IPA Announces New Office Bearers

Mr Satish Reddy, Chairman of Dr Reddy’s Laboratories has been appointed as President of the IPA for 2019-2021. Dr Rajesh Jain, Managing Director of Panacea Biotec Limited will continue as the Vice President.

Mr Satish Reddy holds a degree in Chemical Engineering from Osmania University, India, and an M.S. in Medicinal Chemistry from Purdue University, USA, where he received the 2009 Distinguished Alumnus Award from the School of Pharmacy and Pharmaceutical Sciences.

As an active member of major industry associations and governmental panels, Mr Reddy played a key role in shaping policies concerning the pharmaceutical sector as well as the economy, such as policy formulation on India's patent law, drug pricing and important amendments to the Drugs & Cosmetics Act. He was a past president of IPA (2013-2015), a member of the Drugs Technical Advisory Board of India, the Chairman of the Andhra Pradesh Chapter of the Confederation of Indian Industries (CII) and head of its National Committee on Pharmaceuticals. Mr Reddy, currently Chairs the Life Sciences Skill Development Council under The National Skill Development Corporation (NSDC). In addition, he is Chairman of Dr Reddy’s Foundation.

Mr Reddy led Dr Reddy’s transition from a uni-focused manufacturer of APIs (active pharmaceutical ingredients) to a company that moved up the value-chain with a diverse product portfolio of Finished Dosage Formulations. He oversaw the expansion and establishing of a strong footprint for Dr. Reddy's finished dosage products in US, Russia, CIS countries and other emerging markets.

Dr Rajesh Jain is Managing Director of Panacea Biotec, a leading Biotechnology Company employing over 2,500 people. He provides strategic leadership, management and guidance to the company. He has extensive experience and qualifications in biotechnology and is responsible for Innovation and Business Development.

Dr Jain is a science graduate and holds a PhD in Management. He has authored two position papers for CII: Guideline Changes in Vaccine Approval Procedures and Regulatory & Policy Changes for Sustained Competitiveness of the Indian Vaccine Industry.

Dr Jain is an active member of major industry associations and government panels. He is Chairman - Confederation of Indian Industry (CII), National Committee on Biotechnology for 2019-20. He is a member of Central Drug Research Institute (CDRI), Lucknow.
Dr Jain is a recipient of many awards such as India Innovation Award for 2016 and 2015 by Clarivate Analytics and has been appreciated by GAVI and Bill and Melinda Gates Foundation for his commitment towards making affordable vaccines for population across the globe.

At the time when pharmaceutical industry is undergoing a critical phase of its growth and development, foresight and acumen of leadership will be of immense value to the IPA, in particular and to the national industry, in general.

Sudarshan Jain
Secretary General

Encl: IPA Profile, Profiles and Photographs of Mr Satish Reddy and Dr Rajesh Jain

Indian Pharmaceutical Alliance (IPA) represents 24 research based national pharmaceutical companies. Collectively, IPA companies account for over 85 per cent of the private sector investment in pharmaceutical research and development. They contribute more than 80 per cent of the country's exports of drugs and pharmaceuticals and service over 57 per cent of the domestic market.

For any further queries please contact: Mr Sudarshan Jain at Email: sudarshan.jain@ipa-india.org
Indian Pharmaceutical Alliance (IPA)

About IPA

The Indian Pharmaceutical Alliance (IPA) represents research based national pharmaceutical companies. It consists of following twenty three Members:

Abbott Healthcare Pvt Ltd  Ipca Laboratories Ltd
Ajanta Pharma Ltd  J B Chemicals & Pharmaceuticals Ltd
Alembic Ltd  Lupin Ltd
Alkem Laboratories Ltd  Micro Labs Ltd
Aurobindo Pharma  Mankind Pharma
Cadila Healthcare Ltd  Natco Pharma Ltd
Cadila Pharmaceuticals Ltd  Panacea Biotec Ltd
Cipla Ltd  Sun Pharmaceuticals Industries Ltd
Dr Reddy’s Laboratories Ltd  Torrent Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd  Unichem Laboratories Ltd
Glenmark Pharmaceuticals Ltd  USV Ltd
Intas Pharmaceuticals Ltd  Wockhardt Ltd

Collectively, we account for over 85 per cent of the private sector investment in pharmaceutical research and development. We contribute more than 80 per cent of the country’s exports of drugs and pharmaceuticals and service over 57 per cent of the domestic market.

The main aims of the Indian Pharmaceutical Alliance are:

- Partnering the government in the evolution of a patent regime that will on the one hand meet the TRIPs obligations and on the other serve national interest;
- Engaging the government in constructive dialogue to move to price management from price control regime for the benefit of the consumer;
- Working with the government in progressively upgrading regulatory provisions, procedures and standards to suit the country’s requirements; and
- Helping Indian Pharma Manufacturers to be the global benchmark in Quality.

The pace of reforms in the pharmaceutical industry in India is beginning to accelerate. This will result in increased competition in the domestic market besides offering greater opportunities for Indian companies in the international market. This transition will require an up-gradation of regulatory framework in India, as also better prepare Indian companies to be competitive in the world.

The Indian Pharmaceutical Alliance working closely with Government on policy related matters to help creating an ecosystem for unleashing the potential of Indian Pharmaceutical industry.

For further information, contact: Ms Archana Jatkar
Email: archana.jatkar@ipa-india.org  Tel: 022-2610 9281; Fax: 022-2610 9282
Mr Satish Reddy is the Chairman of Dr. Reddy’s Laboratories. He joined the company in 1993 as Executive Director and since has held positions of increasing responsibility, as Managing Director in 1997 and Vice-Chairman and Managing Director in 2013. Mr. Reddy led the organization’s transition from a uni-focused manufacturer of Active Pharmaceutical Ingredients (APIs) to a company that moved up the value chain, with a diverse portfolio of Finished Dosage Formulations, establishing a strong footprint for Dr. Reddy’s products across the globe.

Mr Reddy drives the organization's corporate social responsibility initiatives and is also Chairman of the Dr. Reddy's Foundation. He is an active member of major industry associations and governmental panels including the Indian Pharmaceutical Alliance. He serves as Chairman of the Board of the Life Sciences Sector Skill Development Council (LSSSDC), which is actively involved in creating an ecosystem for quality education and skill development. He also chairs the Board of Governors of NIPER Hyderabad and is passionate about building NIPER into a world class institute to develop talent for the pharma industry.

Mr Reddy is passionate about enabling access to affordable healthcare and plays a key role in shaping policies concerning the healthcare sector as well as the economy.
Dr Rajesh Jain is Managing Director of Panacea Biotec, a leading Biotechnology Company employing over 2,500 people. He provides strategic leadership, management and guidance to the company. He has extensive experience and qualifications in biotechnology and is responsible for Innovation and Business Development.

Dr Jain is a science graduate and holds a PhD in Management. He has authored two position papers for CII: Guideline Changes in Vaccine Approval Procedures and Regulatory & Policy Changes for Sustained Competitiveness of the Indian Vaccine Industry.

Dr Jain is an active member of major industry associations and government panels. He is Chairman - Confederation of Indian Industry (CII), National Committee on Biotechnology for 2019-20. He is a member of Central Drug Research Institute (CDRI), Lucknow. Dr Jain is a recipient of many awards such as India Innovation Award for 2016 and 2015 by Clarivate Analytics and has been appreciated by GAVI and Bill and Melinda Gates Foundation for his commitment towards making affordable vaccines for population across the globe.